Bristol Myers Squibb is committed to helping appropriate patients get access to our
medications by providing access and reimbursement support services.

This information is intended for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.

Billing and
Diagnosis Codes

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Reimbursement and Coding Guide for REBLOZYL
Download

Filter by keyword Clear Filter
Type a keyword to find a specific HCPCS, CPT, NDC, or ICD-10 code
Healthcare Common Procedure Coding System (HCPCS) Codes1 Issued by CMS
J0896

COPY

Injection, luspatercept-aamt, 0.25 mg

Revenue Codes (for Hospital Use)2
0636

COPY

Drugs requiring detailed coding

0250

COPY

Pharmacy (General)

Current Procedural Terminology (CPT)3†
96372

COPY

Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

96401 (for potential use only in MDS)

COPY

Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

National Drug Codes (NDC)4 Issued by the FDA Note: Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.
59572-0711-01

COPY

25 mg lyophilized powder in a single-dose vial for reconstitution

59572-0775-01

COPY

75 mg lyophilized powder in a single-dose vial for reconstitution

International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)5

Beta Thalassemia
D56.1

COPY

  • Beta thalassemia major
  • Cooley’s anemia
  • Homozygous beta thalassemia
  • Severe beta thalassemia
  • Thalassemia intermedia
  • Thalassemia major
D56.5

COPY

Hemoglobin E-beta thalassemia

Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS) or with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
D46.1

COPY

Refractory anemia with ring sideroblasts

D46.A

COPY

Refractory cytopenia with multilineage dysplasia

D46.B

COPY

Refractory cytopenia with multilineage dysplasia and ring sideroblasts

D46.4

COPY

Refractory anemia, unspecified

REBLOZYL may be purchased through the distributors listed below.

Community Practices

Authorized Distributor Phone Fax
Cardinal Specialty 1-877-453-3972
McKesson Specialty Health 1-800-482-6700 1-800-289-9285
Oncology Supply 1-800-633-7555 1-800-248-8205

For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain REBLOZYL from the distributors listed above.

Institutions/Hospital Outpatient Facilities

Authorized Distributor Phone Orders Fax Orders
AmerisourceBergen 1-844-222-2273 1-888-292-9774
ASD Healthcare 1-800-746-6273 1-800-547-9413
Cardinal Specialty 1-866-677-4844
McKesson Pharma 1-855-625-6285 1-800-599-9893

Puerto Rico Hospitals and Clinics

Authorized Distributor Phone Orders Fax Orders and Website
Cardinal Health P.R. 1-787-625-4200
Cesar Castillo, Inc. 1-787-641-5242 (Hospitals)
1-787-641-5082 (Specialty Pharmacy)
1-787-999-1614

Above information is accurate as of 05/21.

The REBLOZYL distribution program includes extended payment terms to Bristol Myers Squibb authorized REBLOZYL distributors. Healthcare providers and institutions should contact their REBLOZYL distributor to understand specific payment terms that may be available to them from their distributor.

Please see U.S. Full Prescribing Information for REBLOZYL.

FDA Approval Letters as Posted by the FDA:

For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
View Letter

For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
View Letter

Please see U.S. Full Prescribing Information for REBLOZYL.

Coding for REBLOZYL is dependent on the insurer and the care setting in which the drug will be administered. Oncology practices need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.

Please see U.S. Full Prescribing Information for REBLOZYL.

*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.

CPT codes and descriptions only are ©2019 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

References:

  1. Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions: First Quarter, 2020 Coding Cycle for Drug and Biological Products. https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-1-2020-drugs-and-biologicals-updated-04142020.pdf. Accessed March 19, 2021.
  2. Palmetto GBA. Medicare Part A Billing Guide. May 2017. http://www.palmettogba.com/Palmetto/Providers.Nsf/files/Part_A_Billing_Guide.pdf/$File/Part_A_Billing_Guide.pdf. Accessed June 22, 2020.
  3. American Medical Association. CPT Professional 2020. Professional ed. Chicago, IL: American Medical Association; 2019.
  4. REBLOZYL [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  5. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. Accessed March 8, 2021. https://www.cms.gov/Medicare/Coding/ICD10/2020-ICD-10-CM.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Support Center icon
Support Center: 1-800-861-0048
am to 8 pm ET, Mon - Fri
Schedule a Call icon
Schedule a call from a Care CoordinatorSchedule a Call >
Request a Visit icon
Request a visit from a BMS Access & Reimbursement ManagerRequest a Visit >
Schedule a Call Request a Visit >
BMS Logo

2007-US-2100186 06/21

©2021 Bristol-Myers Squibb Company. All rights reserved. Access Support is a registered trademark of Bristol-Myers Squibb Company. REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

Use of the information on this site is subject to the terms of our Legal Notice and Privacy Statement. The coding, coverage, and payment information contained within this website is current as of 05/21.

2007-US-2100074 05/21